The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer.
The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer.
复制标题
免疫检查点阻断和血管生成抑制剂联合治疗晚期非小细胞肺癌。
DOI：
10.3389/fimmu.2021.689132
复制
发表时间：
2021
影响因子：
7.3
通讯作者：
Zhou P
中科院分区：
文献类型：
--
作者：
Ren S;Xiong X;You H;Shen J;Zhou P
免疫检查点阻断（ICB）已成为非小细胞肺癌（NSCLC）的标准治疗方法。然而，大多数非小细胞肺癌患者不能从这些治疗中获益。异常的血管系统是实体瘤的标志，并参与肿瘤的免疫逃逸。这些异常源于促血管生成因子的表达增加，而促血管生成因子参与免疫细胞功能和迁移的调节。抗血管生成药物通过增加免疫细胞的浸润和活化，使血管正常化，从而使肿瘤微环境由免疫抑制向免疫支持转变。因此，免疫治疗与抗血管生成相结合是一种很有前途的癌症治疗策略。本文概述了目前对血管内皮生长因子/血管内皮生长因子受体（VEGF/VEGFR）信号在肿瘤免疫逃逸和进展中的作用机制的认识，并总结了ICB联合抗血管生成药物治疗晚期NSCLC的临床前研究和目前的临床数据。
Immune checkpoint blockade (ICB) has become a standard treatment for non-small cell lung cancer (NSCLC). However, most patients with NSCLC do not benefit from these treatments. Abnormal vasculature is a hallmark of solid tumors and is involved in tumor immune escape. These abnormalities stem from the increase in the expression of pro-angiogenic factors, which is involved in the regulation of the function and migration of immune cells. Anti-angiogenic agents can normalize blood vessels, and thus transforming the tumor microenvironment from immunosuppressive to immune-supportive by increasing the infiltration and activation of immune cells. Therefore, the combination of immunotherapy with anti-angiogenesis is a promising strategy for cancer treatment. Here, we outline the current understanding of the mechanisms of vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) signaling in tumor immune escape and progression, and summarize the preclinical studies and current clinical data of the combination of ICB and anti-angiogenic drugs in the treatment of advanced NSCLC.
登录
查看更多内容
影响因子：
16.6
作者：
Doemling, Alexander;Holak, Tad A.
通讯作者：
Holak, Tad A.
影响因子：
158.5
作者：
Finn, Richard S.;Qin, Shukui;Cheng, Ann-Lii
通讯作者：
Cheng, Ann-Lii
DOI：
10.1084/jem.190.10.1417
发表时间：
1999-11-15
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Bell D;Chomarat P;Broyles D;Netto G;Harb GM;Lebecque S;Valladeau J;Davoust J;Palucka KA;Banchereau J
通讯作者：
Banchereau J
影响因子：
4.8
作者：
Deng, Lei;Stafford, Jason H.;Liu, Shie-Chau;Chernikova, Sophia B.;Merchant, Milton;Recht, Lawrence;Brown, J. Martin
通讯作者：
Brown, J. Martin
影响因子：
8.8
作者：
Alfaro, C.;Suarez, N.;Gonzalez, A.;Solano, S.;Erro, L.;Dubrot, J.;Palazon, A.;Hervas-Stubbs, S.;Gurpide, A.;Lopez-Picazo, J. M.;Grande-Pulido, E.;Melero, I.;Perez-Gracia, J. L.
通讯作者：
Perez-Gracia, J. L.